Pfizer's tafamidis meets in Phase III for TTR cardiomyopathy

Pfizer Inc. (NYSE:PFE) said tafamidis meglumine met the primary endpoint in the Phase III ATTR-ACT trial to treat transthyretin (TTR) cardiomyopathy. Compared with placebo, the therapy reduced a combination of all-cause mortality and frequency of cardiovascular-related hospitalizations at 30 months.

Pfizer said it plans to discuss the data with regulators to determine a path forward. Tafamidis is a small molecule that stabilizes the TTR protein and prevents its misfolding...